Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

Share Price is delayed by 15 minutes
Get Live Data
98.90    -1.20 (-1.20%)
Bid:
99.22
Ask:
99.28
Spread: 0.06 (0.06%)
Market Cap: £57.64b
LLOY Live PriceLast checked at - London Stock Exchange

Intraday Lloyds Share Chart

Publication of Suppl.Prospcts

24 Oct 2025 09:30

RNS Number : 7601E
Lloyds Bank PLC
24 October 2025
 

 

24 October 2025

Publication of Supplementary Prospectus

The following Supplementary Prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Supplementary Prospectus dated 24 October 2025 (the "Supplementary Prospectus") relating to the £35,000,000,000 Euro Medium Term Note Programme of Lloyds Bank plc.

The Supplementary Prospectus should be read and construed in conjunction with the prospectus dated 28 March 2025, as supplemented by the supplementary prospectuses dated 2 May 2025, 24 July 2025 and 5 August 2025 relating to the above programme (the "Prospectus").

To view the Supplementary Prospectus, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/7601E_1-2025-10-24.pdf

The Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Investor Relations:

Douglas Radcliffe

Group Investor Relations Director

Tel: +44 (0) 20 7356 1571

Email: douglas.radcliffe@lloydsbanking.com

 

Group Corporate TreasuryKristofer MiddletonHead of Term Issuance and Capital Structuring

Tel: +44 (0) 207 356 1122

Email: Kristofer.Middleton@lloydsbanking.com

 

Group Corporate Affairs:

Matt Smith

Head of Media Relations

Tel: +44 (0) 7788 352 487

Email: matt.smith@lloydsbanking.com

Lloyds Bank plc

25 Gresham Street,

London EC2V 7HN

United Kingdom

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in this announcement and the Supplementary Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Supplementary Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Supplementary Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Supplementary Prospectus.

In particular, this announcement and the Supplementary Prospectus do not constitute an offer or invitation to subscribe for, or purchase securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Supplementary Prospectus are not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPFIFFTITLSFIE
Date   Source Headline
10th Dec 20254:39 pmRNSDirector/PDMR Shareholding
9th Dec 20254:00 pmRNSDirector/PDMR Shareholding
9th Dec 20257:03 amRNSCompletion of £1.7 billion Share Buyback Programme
8th Dec 20255:42 pmRNSTransaction in Own Shares
5th Dec 20255:50 pmRNSTransaction in Own Shares
4th Dec 20255:38 pmRNSTransaction in Own Shares
3rd Dec 20255:44 pmRNSTransaction in Own Shares
2nd Dec 20255:35 pmRNSTransaction in Own Shares
2nd Dec 20257:39 amRNSBoE Stress Test Passed
1st Dec 20255:31 pmRNSTransaction in Own Shares
28th Nov 20254:12 pmRNSTotal Voting Rights
27th Nov 20255:34 pmRNSTransaction in Own Shares
26th Nov 20255:38 pmRNSTransaction in Own Shares
25th Nov 20255:20 pmRNSTransaction in Own Shares
24th Nov 20255:41 pmRNSTransaction in Own Shares
21st Nov 20255:43 pmRNSTransaction in Own Shares
21st Nov 20253:00 pmRNSDirector/PDMR Shareholding
20th Nov 20255:28 pmRNSTransaction in Own Shares
20th Nov 20253:00 pmRNSBlock Listing of Shares
19th Nov 20255:38 pmRNSTransaction in Own Shares
19th Nov 20251:20 pmRNSDirector Declaration
19th Nov 20257:00 amRNSCurve Acquisition
18th Nov 20255:35 pmRNSTransaction in Own Shares
17th Nov 20255:40 pmRNSTransaction in Own Shares
14th Nov 20255:53 pmRNSTransaction in Own Shares
13th Nov 20255:27 pmRNSTransaction in Own Shares
12th Nov 20255:32 pmRNSTransaction in Own Shares
11th Nov 20255:33 pmRNSTransaction in Own Shares
11th Nov 20253:40 pmRNSDirector/PDMR Shareholding
10th Nov 20255:35 pmRNSTransaction in Own Shares
7th Nov 20255:42 pmRNSTransaction in Own Shares
6th Nov 20255:39 pmRNSTransaction in Own Shares
6th Nov 20252:33 pmRNSPublication of Final Terms
6th Nov 202510:32 amRNSDirector/PDMR Shareholding
5th Nov 20255:34 pmRNSTransaction in Own Shares
4th Nov 20255:42 pmRNSTransaction in Own Shares
3rd Nov 20255:45 pmRNSTransaction in Own Shares
31st Oct 20255:47 pmRNSTransaction in Own Shares
31st Oct 20254:38 pmRNSTotal Voting Rights
30th Oct 20255:16 pmRNSTransaction in Own Shares
29th Oct 20255:40 pmRNSTransaction in Own Shares
29th Oct 202510:31 amRNSNotification of Redemption
28th Oct 20255:29 pmRNSTransaction in Own Shares
27th Oct 20255:29 pmRNSTransaction in Own Shares
24th Oct 20255:56 pmRNSTransaction in Own Shares
24th Oct 202511:33 amRNSPublication of Suppl.Prospcts
24th Oct 20259:30 amRNSPublication of Suppl.Prospcts
23rd Oct 20255:49 pmRNSTransaction in Own Shares
23rd Oct 202512:25 pmRNSPublication of Suppl.Prospcts
23rd Oct 202511:58 amRNS2025 Q3 Interim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.